About
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom. Address: 75/76 Wimpole Street, London, United Kingdom, W1G 9RT
Company Website : http://www.akaritx.com
Address : 75/76 Wimpole Street, London, United Kingdom, W1G 9RT
Employees : 10
Fiscal Year End : December
Currency:
USD
Country :
USA